The Avon Foundation (AF), National Institutes of Health National Cancer Institute (NCI) and Center for Advancing Innovation (CAI) have partnered to launch a “first of a kind” Business Plan and Start-Up Challenge for Breast Cancer (BC) inventions that have high commercial viability and are important to public health. This challenge will accelerate the commercialization of Federal agency and AF grantee BC inventions, spur economic growth, and provide Universities a platform to further develop their entrepreneurship learning portfolio.Continue reading→

NCI PREVENT Cancer Program

The NCI PREVENT Cancer Program provides resources to move novel cancer-preventive chemical or biological agents and biomarkers towards clinical testing. Through a partnership with NCI, promising chemopreventive agents will be optimized and tested with the goals of filing an Investigational New Drug application with the U.S. FDA and entering the agent into clinical testing. Click here to learn more. The next deadline to apply is October 7, 2013.

NCI NExT Program

The NCI Experimental Therapeutics (NExT) Program consolidates NCI’s anticancer drug discovery and development resources in support of a goal-driven therapeutics pipeline. NCI partners with researchers from industry or academia to facilitate the milestone-driven progression of new anticancer drugs and imaging agents towards clinical evaluation and registration. Click here to learn more. The next deadline to apply is October 15, 2013.

NCI CADP

The NCI Clinical Assay Development Program (CADP) provides resources for clinical assay validation to assist with the development of assays that may predict therapy response or prognostic behavior of a diagnosed cancer, primarily for use in clinical trials. Click here to learn more. The next deadline to apply is October 15, 2013.

NCATS Therapeutics for Rare and Neglected Disease (TRND) Program

The National Center for Advancing Translational Sciences (NCATS) is pleased to announce an open opportunity to submit proposals to collaborate with the Therapeutics for Rare and Neglected Diseases (TRND) program.

The TRND program supports preclinical and early clinical development of new drugs for rare and neglected tropical diseases by establishing collaborative partnerships with external researchers. Intended candidates for collaboration will be researchers who have promising leads and disease/target knowledge, but who lack the expertise or resources to fully develop these projects into clinical stage programs attractive to biopharmaceutical or other suitable organizations. TRND seeks to partner with academic laboratories, not-for-profit organizations, and for-profit companies. Foreign organizations are eligible to apply. TRND provides significant in-kind research support, but no direct external funding is available.Interested applicants may visit TRND on the web to learn more about the program, and can refer to the current NIH Guide Notice for more information.

Interested applicants must contact the TRND Solicitation Coordinator by email (TRND@mail.nih.gov) to initiate a pre-screening / Letter of Intent (LOI) process. Applications are made through the online proposal system, proposalCENTRAL (https://proposalcentral.altum.com/).

LOIs must be completed no later than September 16, 2013. Final applications are due by September 30, 2013.